TORONTO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX
Venture:ARCH)(OTCBB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro Technics in Scarborough,
Ontario to perform preclinical toxicology and pharmacology studies for Metablok, the Company’s drug candidate for treating
inflammation, cancer metastasis and sepsis.
Nucro-Technics will be performing toxicology and pharmacokinetic studies to support a pre- Investigational New
Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) planned for early 2018. Arch is preparing an IND application
and a Phase I human clinical trial to evaluate Metablok’s safety and pharmacokinetic profile in advance of future clinical trials
to test its efficacy in treating or preventing acute kidney injury.
In pre-clinical studies, Arch scientists have demonstrated Metablok’s ability to prevent acute kidney injury by
blocking the inflammatory response triggered by kidney ischemia/reperfusion. Currently, there are no specific or effective
treatments to prevent acute kidney injury.
About Nucro-Technics:
Nucro-Technics is Canada’s largest privately held, single-site pharmaceutical contract service organization.
Specialized in pre-clinical research and development, Nucro-Technics has been in business for over 45 years servicing its clients
in a professional and timely manner. The multidisciplinary services offered on-site allow the organization to function as a
single-point-of contact for companies that need to fulfill IND testing requirements to bring their products through to the next
phase of drug development.
Nucro-Technics is in compliance with both FDA and Health Canada regulations, and has been accredited as a GLP
facility by the Standards Council of Canada to the OECD standard. As such, Nucro-Technics has a long history of providing GLP and
GMP-compliant contracted research and development services to a wide array of pharmaceutical and biotech firms, both large and
small.
For additional information on Nucro-Technics, the single destination for a company’s contract research and
support needs, please visit www.nucro-technics.com or call (416) 438-6727.
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a
significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions
to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create
value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant
bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive
brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various
medical grade metals and plastics.
For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies
including, please visit www.archbiopartners.com
The Company has 55,299,679 common shares outstanding.
For more information, please contact:
Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements
that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives
of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could
differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements
are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by
this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates
or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
